NCT05580146 is a NA clinical trial of Zynamite® 15% 150mg in Cognitive Change, sponsored by Northumbria University.

Who is sponsoring NCT05580146?

NCT05580146 is sponsored by Northumbria University.

What drugs are being tested in NCT05580146?

Interventions in NCT05580146: Zynamite® 15% 150mg, Zynamite® 15% 300mg, Zynamite® 15% 600mg, Placebo.

What condition does NCT05580146 study?

NCT05580146 studies Cognitive Change.

Is NCT05580146 still recruiting?

NCT05580146 is currently completed. Last updated 14 October 2022.

Last reviewed 2022-10-14 · How we verify

NCT05580146

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Dose-ranging Effects of Mango Leaf Extract (Zynamite® 15%) on Cognitive Function and Cerebral Blood Flow

Completed NA Last updated 14 October 2022

What this trial tests

NA trial testing Zynamite® 15% 150mg in Cognitive Change in 62 participants. Completed in 14 April 2022.

Timeline

17 May 2021

Primary endpoint
14 April 2022

14 April 2022

Quick facts

Lead sponsor	Northumbria University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	other
Enrollment	62
Start date	17 May 2021
Primary completion	14 April 2022
Estimated completion	14 April 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Zynamite® 15% 150mg
Zynamite® 15% 300mg
Zynamite® 15% 600mg
Placebo

Conditions studied

Cognitive Change — all drugs for Cognitive Change →

Sponsor

Northumbria University

Who can join

Adults 18 to 30, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain polyphenol mangiferin.It has previously been shown to enhance brain oxygenation, physical performance and ergogenic parameters following ischemia-reperfusion in healthy humans when consumed alongside other polyphenols. Preliminary data has also indicated that a single 300mg dose of Zynamite® (60%) can improve performance across a range of cognitive tasks.This study aims to evaluate the effects, in healthy adults, of 3 doses of Zynamite® 15% on performance across a number of cognitive domains, as well as during a period of cognitively demanding task performance. A second sub-study will assess cerebral blood flow during cognitively demanding task performance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cognitive Change

Currently open trials in the same condition.

NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
NCT07054723 — Surviving Daily Life · recruiting

Other Northumbria University trials

Trials by the same sponsor.

NCT07501611 — Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation · NA · not yet recruiting
NCT07242430 — 12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
NCT07235878 — 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
NCT07297485 — Evaluating the Level of Agreement Between Goniometer Measurements and Algorithm to Determine Wall Squat Position · completed
NCT06967454 — Manipulation of Whey Permeate Formulation for Better Fluid Retention. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05580146 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northumbria University
Last refreshed: 14 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05580146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing